$AI

SIEBEL THOMAS M sold $5.5M of AI

SIEBEL THOMAS M (CEO and Chairman of the Board) sold 495,575 shares of C3.ai, Inc. (AI) at an average of $11.10 ($10.92–$11.11, $5.50M total) across 2 trades over 2026-06-12 to 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · SIEBEL THOMAS M
Published Jun 16, 2026, 12:04 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 16, 2026, 12:34 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AI
Neutral
medium confidence
Mentioned
$AI
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AINeutralLow
01

Why it matters

The newest information is the disclosed sale size, execution window, and weighted-average price, plus confirmation it was under a pre-arranged 10b5-1 plan.

02

Market read

Provides a concrete insider-selling datapoint for AI, but the 10b5-1 structure suggests limited fundamental signal.

03

What to watch

Traders may over-weight insider sales; the article lacks any accompanying fundamental update (earnings, guidance, contracts) that would justify repricing.

Relevance 5/10Novelty 5/10Timing: Filed 2026-06-15 after trades dated 2026-06-12 to 2026-06-15

Background

The filing is an SEC Form 4 insider transaction for C3.ai, Inc. (AI) by CEO/Chairman Thomas M. Siebel.

Company-level read

Ticker impact

$AINeutralMedium confidence
Context

C3.ai CEO/Chairman Thomas M. Siebel sold 495,575 shares in open-market trades at ~$10.92–$11.11 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect is more about sentiment/positioning than fundamentals.

Evidence & confidence

Form 4 provides concrete transaction details, yet the article specifies the sales were executed under a pre-arranged 10b5-1 plan, which typically dampens interpretability versus discretionary selling.

Market effects

Adds incremental sentiment data for AI software/enterprise AI names, but no sector-wide catalyst is introduced.

No clear regional linkage beyond US-listed insider activity.

No direct global linkage; transaction is company-specific and US-listed.

Counterpoint

Because the sales were executed under a pre-arranged 10b5-1 plan, the disclosure may reflect routine liquidity rather than bearish expectations.

Key entities

  • C3.ai, Inc.

    US-listed AI software company; subject of the insider Form 4 disclosure.

  • Thomas M. Siebel

    CEO and Chairman; 10% owner who sold shares in open-market trades under a 10b5-1 plan.

Related articles

$AIMed

Trump Family Pockets Half A Billion As Trump-Backed Crypto Firm Moves To Sell Only Revenue-Generating Business

The Wall Street Journal reports Nasdaq-listed AI Financial (formerly Alt5 Sigma) is in talks to sell its only revenue-generating payments subsidiary to Tokyo-based Perpetuals.com for up to $15 million. The unit generated about $25 million revenue in 2024. AI Financial’s losses followed World Liberty’s August 2025 WLFI token purchase and WLFI’s ~70% decline, with AI Financial reporting a $271 million quarterly loss.

$AIMedAI 9/10

C3.ai Q4 2026 Earnings Call Transcript - C3.ai (NYSE:AI)

C3.ai held its Q4 earnings call, reporting total revenue of $51.6 million, with subscription revenue 94% of the total. The company said it cut headcount about 35% and expects ~$135 million in annual operating cost savings. CEO Tom Siebel cited poor sales execution and plans to expand its target accounts. FY2027 guidance calls for $210–$240 million revenue and non-GAAP operating loss of $128–$160 million.

$AIHighAI 9/10

Live: Will C3.ai Beat Q4 Earnings After the Bell Tonight?

C3.ai (AI) reports Q4 fiscal 2026 results after the close. The company is focused on revenue within guidance ($48.0M–$52.0M), improving GAAP gross margin from 17% (down from 59% a year earlier), and expanding federal bookings, which rose 134% YoY to 55% of total bookings. Wall Street has 6 sell and 7 hold ratings; average target is $8.82 vs. $10.51.

$AIMedAI 8/10

Wall Street Has a Consensus on This AI Stock. The Consensus Is Dead Wrong.

The article argues that Wall Street’s consensus on C3.ai (AI) is inconsistent and may not reflect deteriorating fundamentals. It cites a hold consensus from 12 analysts with an average price target near $17 versus a stock price around $9.50. For fiscal Q1 2026 ended July 31, C3.ai reported about $50M revenue, missed guidance, posted a $0.40 loss per share vs $0.30 estimate, and guided continued pressure.

$AIMedAI 9/10

Thomas Siebel Is Back as C3.ai CEO. Will This Help the Stock Rebound?

C3.ai shares are down 59% over 12 months as the company’s sales have declined, despite having 100+ enterprise AI turnkey solutions. After CEO/founder Thomas Siebel stepped down in 2024 for health reasons and Stephen Ehikian took over Sept. 1, 2025, C3.ai reported preliminary Q4 revenue of $51.6M vs. $108.7M a year earlier. The company says Siebel returned as CEO May 8.